Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland

Abstract

To assess the long-term visual outcomes in eyes with symptomatic diabetic macular oedema (DME) under intravitreal treatment (IVT) in a clinical routine setting. Patients with newly diagnosed DME were included in this retrospective study if they had received at least three IVTs and a follow-up period\u2009≥\u20092 years. Due to altered treatment patterns since the approval of ranibizumab for DME in 2012, patients were subdivided according to their first IVT before 2013 (group 1) or thereafter (group 2). The primary outcome measure was the evolution of best-corrected visual acuity (BCVA) over time. Of 217 eyes (191 patients) with DME, 151 eyes (117 patients) fulfilled the inclusion criteria (63 eyes in the first period, 88 in the second period). Mean follow-up time was 7.9\u2009±\u20093.1 (group 1) and 4.1\u2009±\u20091.4 years (group 2; p\u2009<\u20090.001). Visual gains were similar in the first year (group 1:\u2009+\u20095.3\u2009±\u200915.5, group 2:\u2009+\u20097.3\u2009±\u200912.2 Early Treatment Diabetic Retinopathy Study (ETDRS) letters; p\u2009=\u20090.44), but not thereafter (after 2 years in group 1:\u2009+\u20094.4\u2009±\u200915.0, group 2:\u2009+\u20098.3\u2009±\u200913.0 ETDRS letters; p\u2009=\u20090.038). During the first year, group 1 patients received less clinical examinations (group 1: 6.6\u2009±\u20093.3, group 2: 7.5\u2009±\u20092.1; p\u2009=\u20090.007) and less injections (group 1: 3.6\u2009±\u20092.7, group 2: 6.1\u2009±\u20092.7; p\u2009<\u20090.001). A greater visual gain, in response to more intensive treatment during the first year, was maintained for at least 5 years in group 2 subjects. Our data confirm that in a real-world setting, early intensive treatment results in satisfying long-term visual outcomes.